Overview

Study to Assess the Efficacy and Safety of GP681 Tablets in the Treatment of Acute Uncomplicated Influenza Virus Infection

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 to 65 years with acute uncomplicated influenza virus infection
Phase:
Phase 3
Details
Lead Sponsor:
Jiangxi Qingfeng Pharmaceutical Co. Ltd.